Analytical evidence
MOTS-c Sequence Verification: What a Mass Match Can Establish
Define the MOTS-c sequence before reading analytical evidence. Understand mass conventions, sequence coverage and the specific isoleucine/leucine limitation.
In this guide · 7 sections
The short answer
For MOTS-c, a matching molecular mass supports a narrower conclusion than a fully verified sequence. Establish the intended 16-residue structure first, then ask whether the report measures intact mass, sequence-informative fragments or a different property altogether.
This guide explains material identity for laboratory research procurement. It provides no preparation instructions or basis for human or veterinary use.
One detail makes this especially important: the reference MOTS-c sequence includes both isoleucine and leucine. Those residues have the same molecular mass, so their identities cannot be decided from an intact-mass match alone.
Put the reference sequence beside the material description
The PubChem MOTS-c reference record (CID 146675088) displays the sequence MRWQEMGYIFYPRKLR and the expanded notation H-Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH. In that representation, isoleucine is residue 9 and leucine is residue 15.
Keep the full sequence and its terminal notation in the research material specification. The short name is useful for finding a catalogue entry, but it does not independently establish that the supplier’s material has every structural feature shown in a reference record.
If a description includes a terminal modification, residue substitution or other named change, preserve it. Compare the modified structure with the project’s required material before reading a mass as a match. A related name or similar sequence is insufficient to establish equivalence.
The reference record is also not a batch result. It provides a chemical target against which a relevant analytical claim can be examined. It cannot supply an unreported sequence measurement, salt specification or modification assessment for a commercial sample.
Identify the kind of evidence actually supplied
Before looking for a matching number, identify what the document contains. A chromatogram labelled HPLC-UV is a different kind of record from a mass spectrum or a sequence-assignment table.
The published MOTS-c laboratory document numbered PBC-MOTS-10-082026 presents HPLC-UV purity and content analysis. It does not display a mass spectrum or residue-by-residue sequence assignment. This describes the scope visible in that document; it does not establish what other information may exist.
Read any future or additional identity evidence on its own terms. The MOTS-c product record and results ledger are the starting points for locating the relevant document. Do not transfer a result from a different product amount or lot because the compound name is the same.
Compare mass values on the same basis
A mass comparison needs a defined structure and a defined convention. IUPAC distinguishes average mass, which accounts for isotopic composition, from monoisotopic mass, calculated using the most abundant isotope of each element.
An instrument’s m/z value adds the ion’s charge state to the interpretation. The IUPAC mass-to-charge terminology explains why a displayed ion value should not simply be compared with a neutral molecular-weight field.
For MOTS-c, ask the laboratory to identify:
The sequence and terminal groups used for the expected value
Whether the reported comparison uses average or monoisotopic mass
The assigned ion and charge state, or how a neutral mass was obtained
The acceptance criterion used for the comparison
These details belong with the result. Avoid supplying a missing expected value from a different website, especially when the reference includes an unspecified salt or modification. Numerical agreement is meaningful only after the comparison basis is aligned.
Why the correct intact mass does not settle residue order
An intact-mass result measures the mass of the assigned intact species. It does not directly list the residues from position 1 through position 16.
There is a simple compositional reason for this limitation: rearranging the same residues without changing the termini leaves the same overall elemental composition. The expected intact mass consequently cannot, by itself, select the correct order from those arrangements. This is a chemical inference about the information contained in the measurement, not an allegation that a particular MOTS-c batch contains a rearranged sequence.
Sequence-informative fragmentation can address more of that question. When a report claims sequence confirmation, look for the assigned fragments, which parts of the expected sequence they cover, and any unresolved positions. A summary reading “mass matches” does not describe that coverage.
The appropriate level of evidence depends on the project’s defined identity question. The purpose is to describe the conclusion accurately, rather than to demand every available analytical technique for every purchase.
The specific isoleucine and leucine problem
In the reference MOTS-c sequence, positions 9 and 15 deserve explicit attention when the question requires those residues to be distinguished. Leucine and isoleucine are isomeric residues with the same mass. Increasing the precision of an intact-mass measurement does not make their masses different.
Some specialised mass-spectrometric strategies can distinguish them. Xiao, Vecchi and Wen’s 2016 study of Leu/Ile assignment demonstrated an integrated approach using multistage fragmentation. That result supports a method-specific conclusion; it does not mean that every document labelled MS/MS resolves these residues.
For a particular report, distinguish fragments that establish the peptide backbone from observations that discriminate the Leu and Ile side chains. A method demonstration using another peptide cannot establish those assignments for a Peptide Confidential sample.
A useful question for a MOTS-c sequence claim is therefore: “Does the reported method distinguish Ile at position 9 from Leu at position 15, or are those assignments based on the expected sequence?”
Record the answer at that level. Do not replace it with the blanket assertion that mass spectrometry either always can or never can resolve the distinction.
Choose the next question from the evidence
| What the document shows | The next identity question | A conclusion to avoid |
|---|---|---|
| HPLC-UV result without mass data | What separate evidence addresses the specified MOTS-c structure? | Calling the chromatogram a sequence confirmation |
| An intact-mass match | Was residue order independently examined? | Describing all 16 positions as verified |
| Sequence fragments with coverage stated | Which positions or alternatives remain unresolved? | Assuming coverage is complete without reading it |
| A claim of Leu/Ile discrimination | Which distinguishing fragment evidence supports those assignments for this sample? | Applying a method demonstration from another peptide directly to the batch |
| A modified sequence or unclear termini | Is this the material the project specifies? | Comparing its result with an unmodified reference by name alone |
If additional evidence is needed, the guide to independent peptide laboratory checks helps turn the unresolved question into a bounded request.
For a Canadian MOTS-c procurement comparison, resolve the structure and evidence scope before comparing price or order terms. Use the Canadian supplier-comparison guide for that wider decision.
The useful outcome is a precise statement of what the record supports: a chromatographic finding, an intact-mass match, a sequence assignment with defined coverage, or a remaining identity question. Keeping those conclusions distinct makes the documentation usable for the research decision it is meant to support.
Sources and scope
The IUPAC definitions explain the mass conventions. The PubChem record and the study named in the text are cited for the reference sequence and the leucine/isoleucine method only. The evidence table is an original editorial tool, and the MOTS-c document discussed is identified by its report number: what it shows applies to that document.
Published by Peptide Confidential, a commercial supplier of research materials. Apply these checks to our documentation as well as another supplier’s.